Isomorphic Labs

Extracted Attributes

• CEO

  Demis Hassabis

• COO

  Pamela Carroll

• CSO

  Miles Congreve

• CTO

  Sergei Yakneen

• CAIO

  Max Jaderberg

• Founded

  2021-02-24

• Founder

  Demis Hassabis

• Mission

  Use AI to accelerate drug discovery and find cures for humanity's most devastating diseases

• Industry

  Drug discovery

• Company Type

  Subsidiary

• Headquarters

  London, United Kingdom

• Key Technology

  AlphaFold

Timeline

• Isomorphic Labs Limited was incorporated. (Source: Wikidata, Web search (Wikipedia))

  2021-02-24

• Isomorphic Labs was publicly announced by Demis Hassabis. (Source: Web search (isomorphiclabs.com blog))

  2021-11-01

• Isomorphic Labs was announced (alternative date). (Source: DBPedia)

  2021-11-05

• Isomorphic Labs announced its second office location in Lausanne, Switzerland. (Source: Web search (Wikipedia))

  2022-12-01

• Isomorphic Labs partnered with Novartis AG and Eli Lilly and Company for AI drug discovery and research. (Source: Web search (Wikipedia), Related documents)

  2024-01-01

• Isomorphic Labs raised $600 million in its first financing round. (Source: Web search (clinicaltrialsarena.com))

  2025-03-01

• Isomorphic Labs aims to initiate clinical trials for its AI-developed oncology drugs. (Source: Web search (clinicaltrialsarena.com))

  2025-07-07

Web Search Results

• Isomorphic Labs - Wikipedia

  Isomorphic Labs Limited is a London-based company which uses artificial intelligence for drug discovery. Isomorphic Labs was founded by Demis Hassabis, who is the CEO. The company was incorporated on February 24, 2021 and announced on November 4, 2021. It was established under Alphabet Inc. as a spin-off from its AI research lab DeepMind, of which Hassabis is also founder and CEO. [...] The company draws upon DeepMind's AlphaFold technology, which can be used to predict protein structures in the human body with high accuracy, allowing its researchers to find new target pathways for drug delivery. In December 2022, Isomorphic Labs announced its second office location in Lausanne, Switzerland. In January 2024, Isomorphic Labs partnered with Novartis AG and Eli Lilly and Company to work together on AI drug discovery and research. [...] Wikipedia The Free Encyclopedia ## Contents # Isomorphic Labs Isomorphic Labs Limited | | | --- | | Company type | Subsidiary | | Industry | Drug discovery | | Founded | 24 February 2021 Edit this on Wikidata | | Founder | Demis Hassabis | | Headquarters | London, United Kingdom | | Key people | Demis Hassabis (CEO) Pamela Carroll (COO) Miles Congreve (CSO) Max Jaderberg (CAIO) Sergei Yakneen (CTO) | | Parent | Alphabet Inc. | | Website | isomorphiclabs.com | Edit this on Wikidata

• Introducing Isomorphic Labs

  Building on this advance, today, I'm thrilled to announce the creation of a new Alphabet company – Isomorphic Labs – a commercial venture with the mission to reimagine the entire drug discovery process from first principles with an AI-first approach and, ultimately, to model and understand some of the fundamental mechanisms of life. [...] Blog 1.11.21 Demis Hassabis # Introducing Isomorphic Labs We are reimagining the entire drug discovery process from first principles with an AI-first approach. Share: 0 a--up a--h-150-100 0 a--up none 1 a--up none 2 a--up none 0 a--up none 1 a--up none 2 a--up none # We are reimagining the entire drug discovery process from first principles with an AI-first approach. ‍ [...] As pioneers in the emerging field of ‘digital biology’, we look forward to helping usher in an amazingly productive new age of biomedical breakthroughs. Isomorphic’s mission could not be a more important one: to use AI to accelerate drug discovery, and ultimately, find cures for some of humanity’s most devastating diseases. Share: 0 a--up No items found. a--up 2 2 1 Slide Fig. Slide Fig. No items found. 0 a--up none Share: 0 a--up none No items found. a--up 2 2 1

• Isomorphic Labs: Reimagining Drug Discovery Process with AI

  Isomorphic Labs was launched in 2021 to advance human health by building on and beyond the Nobel-winning AlphaFold system. Since then, our interdisciplinary team of drug discovery experts and machine learning specialists has built powerful new predictive and generative AI models that accelerate scientific discovery at digital speed.

• How Isomorphic Labs uses machine learning models to explore new ...

  Isomorphic Labs is developing cutting-edge computational techniques to tackle not only some of the hardest problems in drug discovery, but also some of the toughest challenges in biology, chemistry, and medicine. It's exciting that Google Cloud can support this vision, providing the computational power and flexible, scalable infrastructure that are enabling Isomorphic Labs to reimagine scientific research. [...] Isomorphic is Greek for “same shape,” which speaks to the parallel between computational models and life itself. The premise of our company is to build machine learning models that accurately represent the fundamentals of biology and chemistry. With the assistance of these models, we'll be able to remove much of the experimental work from the equation of drug discovery and conduct the search for new medicines in-silco (through virtual computing environments) in a really rapid and efficient way. [...] ### Laying the foundation for accelerated discoveries At Isomorphic Labs, we’re already making massive improvements to drug discovery. Instead of developing narrow solutions for a specific disease, we’re working to understand core aspects of biology and chemistry, and have developed a general platform that we can apply across all disease areas. This type of scalability is what makes technology so powerful.

• Isomorphic Labs prepares to launch trials for AI-designed drugs

  Skip to site menu Skip to page content News # Isomorphic Labs prepares to launch trials for AI-designed drugs The Google DeepMind spinout raised $600m in its first financing round in March 2025. Abigail Beaney July 7, 2025 Share Copy Link Share on X Share on Linkedin Share on Facebook Alphabet’s AI drug development subsidiary Isomorphic Labs is aiming to initiate clinical trials for its AI-developed oncology drugs.

• Instance Of

  Q4830453

• Headquarters

  London

• Inception Date

  2/24/2021

Isomorphic Labs is a drug discovery company launched in the United Kingdom in November 2021. The company was established under London-based AI lab DeepMind, a subsidiary of Alphabet Inc., the parent company of Google. It is led by Demis Hassabis. Isomorphic Labs was incorporated in February 2021 and announced on November 5, 2021. Isomorphic Labs uses artificial intelligence for drug discovery.